NCT03098836 - Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 10, 2017

Primary Completion Date

July 9, 2024

Study Completion Date

July 9, 2024

Conditions

Prostate Cancer

Interventions

DRUG

ARN-509

240 mg orally daily

DRUG

Abiraterone Acetate

1000 mg orally daily

DRUG

Prednisone

5 mg orally twice daily (for total daily dose 10 mg)

Trial Locations (14)

21204

Chesapeake Urology Associates, Baltimore

23502

Virginia Oncology Associates, Norfolk

27514

UNC Lineberger Cancer Center, Chapel Hill

27518

Duke Cancer Center Cary, Cary

27520

Johnston Hematology and Oncology of Clayton, Clayton

27536

Maria Parham Hospital, Henderson

27577

Johnston Memorial Hospital, Smithfield

27710

Duke University Medical Center, Durham

28352

Scotland Memorial Hospital, Laurinburg

28358

Southeastern Regional, Lumberton

29303

Spartanburg Regional, Spartanburg

Virginia Oncology Associates, Hampton

48201

Barbara Ann Karmanos Cancer Institute, Detroit

70112

Tulane University, New Orleans

All Listed Sponsors

collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

Daniel George, MD

OTHER